

May 6, 2016

Company Name: ONO PHARMACEUTICAL CO., LTD.
 Representative: Gyo Sagara, President and Representative Director
 Securities Code: 4528, First Section of the Tokyo Stock Exchange
 Inquiries: Yukio Tani, Director, Corporate Communications
public_relations@ono.co.jp

Notice regarding Differences between Non-consolidated Results for the Fiscal year Ended March 31, 2016 and those for the Previous Fiscal Year

ONO PHARMACEUTICAL CO., LTD. (Osaka, Japan; President and Representative Director, Gyo Sagara; “ONO”) announced today that there have been differences between its non-consolidated results (Japanese standard) for the fiscal year ended March 2016 (April 1, 2015 to March 31, 2016) and those for the previous fiscal year.

Details

1. Differences between the full-year non-consolidated results for the fiscal year ended March 2016 (April 1, 2015 – March 31, 2016) and those for the previous fiscal year

(Unit: Millions of yen, except basic earnings per share)

	Net Sales	Operating Profit	Profit before Tax	Profit (Owners of the Parent Company)	Basic earnings per share (yen)
Previous Results (A) (FY ended March 2015)	134,982	12,941	13,195	9,304	17.55
Revised Results (B) (FY ended March 2016)	159,356	22,657	24,460	20,775	39.19
Change (B – A)	24,374	9,716	11,265	11,470	-
Change (%)	18.1	75.1	85.4	123.3	-

(Note) The company conducted a stock split of common stocks at a ratio of 1:5 with an effective date of April 1, 2016. As for “Basic earnings per share”, it is calculated assuming that the stock split was conducted at the beginning of the previous period.

2. Reasons for the revision

As for the net sales, in addition to the steady sales increase of key new products, the current sales was increased due to an approval of “OPDIVO® Intravenous Infusion”, anti-cancer drug, for additional indication of unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) granted in December 2015. In addition, operating profit, profit before tax and profit for the period was increased, compared to those for the previous year because personnel cost decreased by ¥6.3 billion due to the influence (decrease) of past service cost associated with the revision of retirement benefit scheme.